NASDAQ:RNAZ TransCode Therapeutics Q4 2024 Earnings Report $11.76 -2.13 (-15.33%) Closing price 07/29/2025 04:00 PM EasternExtended Trading$11.95 +0.19 (+1.62%) As of 07/29/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast TransCode Therapeutics EPS ResultsActual EPS-$0.60Consensus EPS -$2.00Beat/MissBeat by +$1.40One Year Ago EPSN/ATransCode Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$0.30 millionBeat/MissN/AYoY Revenue GrowthN/ATransCode Therapeutics Announcement DetailsQuarterQ4 2024Date5/21/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsTransCode Therapeutics' Q2 2025 earnings is scheduled for Wednesday, August 13, 2025, with a conference call scheduled on Tuesday, August 12, 2025 at 12:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesAnnual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsAnnual report(10-K) TransCode Therapeutics Earnings HeadlinesTransCode Therapeutics (NASDAQ:RNAZ) Stock Rating Upgraded by Wall Street ZenJuly 21, 2025 | americanbankingnews.comTranscode Therapeutics Inc News (RNAZ) - Investing.comJuly 4, 2025 | investing.comA $674B Industry Missed the Bigger PictureTV video streaming exploded into a $674.25B market in 2024—driven by the hours we spend lost in entertainment. But there’s a much bigger habit consuming our time, with value that’s waiting to be unlocked. Smartphone screen time. We spend over 30 hours a week glued to our phones. Mode Mobile is pioneering ways to turn those hours into real income. Their EarnPhone unlocks 19 revenue streams from everyday phone use, helping users earn over $325M so far. Deloitte crowned them North America’s fastest-growing software company in 2023 after their revenue soared 32,481% from 2019-2022. But this industry is still in its infancy, and you can invest in the company that’s at the forefront of unlocking its value. | Mode Mobile (Ad)TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory BoardMay 28, 2025 | prnewswire.comTransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities ReportedMay 8, 2025 | prnewswire.comTransCode Therapeutics, Inc.: TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock SplitMay 6, 2025 | finanznachrichten.deSee More TransCode Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like TransCode Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TransCode Therapeutics and other key companies, straight to your email. Email Address About TransCode TherapeuticsTransCode Therapeutics (NASDAQ:RNAZ), Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.View TransCode Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles RCL Stock Sinks After Earnings—Is a Buying Opportunity Ahead?Amazon's Pre-Earnings Setup Is Almost Too Clean—Red Flag?Deckers Stock Recovers on Strong Earnings—More Upside Ahead?3 Reasons Tesla's Post-Earnings Hangover Looks Like a BuyCan Qualcomm Shock Wall Street With Its Q3 Earnings?T-Mobile Earnings Show You Why This Is a Stock to HoldAmerican Airlines Earnings Miss, But Bulls Aren’t Backing Off Upcoming Earnings American Electric Power (7/30/2025)Automatic Data Processing (7/30/2025)ARM (7/30/2025)Equinix (7/30/2025)Robinhood Markets (7/30/2025)Lam Research (7/30/2025)MercadoLibre (7/30/2025)Meta Platforms (7/30/2025)Microsoft (7/30/2025)QUALCOMM (7/30/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
